



# ACT EU multi-stakeholder platform annual meeting

22 October 2024, 09:30 – 17:00 (CET/CEST)

**Hybrid meeting / EMA, Amsterdam**

The success of clinical trials relies on a wide range of stakeholders and therefore regular dialogue between all parties can help to identify and advance clinical trial methods, technology and science, as well as remove barriers. To promote collaboration across different stakeholder groups for the improvement of clinical trials in the EU, the EC-HMA-EMA initiative, Accelerating Clinical Trials in the EU (ACT EU), has established a multi-stakeholder platform (MSP). In addition, with the recent establishment of the MSP Advisory Group (MSP AG), the work of ACT EU is being continuously informed by stakeholder views and can benefit from stakeholders' knowledge and activities in the field of clinical research.

The constant engagement with key stakeholder groups aims to accelerate the improvement of the clinical trials enterprise in the EU by streamlining processes, and reducing administrative burden and complexities.

The MSP annual meeting aims to:

- Review the key achievements of ACT EU since its inception and their impact on clinical research.
- Discuss the current clinical trials landscape, including other key initiatives, and the stakeholder needs for an improved environment.

- Look to the future to visualise what success looks like for different stakeholder groups, and identify quick wins that could drive a rapid change.

**This workshop is open to all stakeholders.**

# ACT EU multi-stakeholder platform annual meeting agenda

Chaired by Maria Jesús Lamas (AEMPS) and Denis Lacombe (EORTC)

**22 October 2024, 09:30 – 17:00 (CET/CEST)**

**09:00**      **Joining and technical checks**

---

**09:30**      **Welcome and opening speech**

---

<b>Co-chairs welcome and opening of the meeting</b>	<b>5'</b>
<b>Welcome from the European Medicines Agency</b>	<b>5'</b>
<b>Opening remarks from the European Commission</b>	<b>5'</b>
<b>Opening remarks from the Heads of Medicines Agencies</b>	<b>5'</b>

**09:50**      **Session 1: Looking back - Overview of ACT EU delivery to date**

---

*Moderators: TBC*

<b>ACT EU update: the journey so far</b>	<b>10'</b>
<b>Consolidated advice on clinical trials</b>	<b>15'</b>
<b>New CTIS transparency rules</b>	<b>10'</b>
<b>The MSP Advisory Group and stakeholders' feedback</b>	<b>25'</b>

**10:50**      **Coffee break**

**11:05**      **Session 2: Clinical trials in Europe at present - ACT EU and beyond**

---

*Moderators: TBC*

<b>What do the numbers tell us?</b>	<b>15'</b>
<b>Exploring the dynamics of partner collaboration with ACT EU</b>	<b>5'</b>
• <b>CTR Collaborate and CTCG action on patient involvement</b>	<b>15'</b>
• <b>CTAG and MedEthicsEU</b>	<b>15'</b>
• <b>COMBINE programme</b>	<b>15'</b>

	<b><i>Panel and audience discussion</i></b>	<b>55'</b>
<b>13:00</b>	<b>Lunch break</b>	
<b>14:00</b>	<b>Session 3: A brighter future for clinical trials in EU &amp; how to get there</b>	
	<i>Moderators: TBC</i>	
	<b>Addressing stakeholder challenges - what's next?</b>	<b>10'</b>
	<b><i>Panel and audience discussions</i></b>	
<b>15:30</b>	<b>Coffee break</b>	
<b>15:45</b>	<b>Session 3: A brighter future for clinical trials in EU - how to get there</b>	
	<i>Moderators: TBC</i>	
	<b>What does a brighter future look like?</b>	<b>5'</b>
	<b><i>Panel and audience discussion</i></b>	<b>50'</b>
	<b>From the theory to the practice, how will we measure success?</b>	<b>10'</b>
<b>16:50</b>	<b>Closing remarks</b>	
	<b>Wrap up</b>	<b>10'</b>